Jazz Pharmaceuticals plc announced that it will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting, scheduled for November 19-23 in Honolulu, Hawaii. The presentations will highlight both clinical and preclinical research related to Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma, as well as new preclinical data on JZP3507 (formerly ONC206) in central nervous system tumors. Key topics include translational research on molecular pathways influencing dordaviprone sensitivity and preclinical findings on how dordaviprone may impact the tumor immune environment. The results are set to be presented at the upcoming SNO meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: SF20684) on November 11, 2025, and is solely responsible for the information contained therein.